drugset / Trial / NCT06137144
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
RandomizedSequentialOpen-labelTreatment
Summary
This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Timeline
- Start
- 2024-01-23
- Primary completion
- 2029-05-03
- Completion
- 2029-05-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD3470 | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |